NeuroAge Therapeutics

What NeuroAge Therapeutics does

NeuroAge Therapeutics, Inc. is a San Francisco-based longevity biotech company founded in 2022 by Dr. Christin Glorioso, MD/PhD, that sells direct-to-consumer multi-modal brain aging assessments. The platform combines four measurement modalities: (1) NeuroGames, an at-home AI cognitive testing and brain training subscription at $9.99/month; (2) volumetric brain MRI analyzed across 25+ regions via partner BrainKey ($1,398 new scan or $399 with existing MRI upload); (3) a proprietary 52-transcript RNA blood biomarker panel measuring hallmarks of brain aging ($899); and (4) Genetic Resilience Analysis covering APOE genotype, a 41-variant Alzheimer's polygenic risk score, longevity genes, and pharmacogenomic markers ($249 with existing data or $799 with whole-genome sequencing). These components are sold individually or bundled into the Essential Bundle ($1,398/year) or the comprehensive NeuroAge Test Ultra ($3,895). The multi-modal model is trained on data from 500,000+ individuals and supported by 20+ years of peer-reviewed research. The company also offers one-on-one coaching with Dr. Glorioso at $280 per 50-minute session.

Revenue is generated primarily through direct-to-consumer e-commerce on its website and app storefront, supplemented by a B2B2C channel through 8+ clinical and longevity clinic partners (PhysioAge, HealthspanSF, Prime Health Associates, California Center for Functional Medicine, and others) and a 72+ center MRI partner network spanning the US, UK, and Canada. The company also runs the Younger 2027 biological aging contest — a six-month event with multi-system testing partnerships (TruDiagnostic epigenetic clocks, FaceAge deep-learning face age, Vero Bioscience proteomic clocks, Yale methylation clocks) — as a brand-building and demand-generation vehicle. An ADDF-funded $250,000 grant supports a 75-participant IRB-approved clinical trial validating the assessment platform.

The company serves primarily prevention-minded adults and individuals with family history of cognitive decline, with secondary segments including high performers/executives, longevity enthusiasts/biohackers, and individuals with MCI or early Alzheimer's disease. All named customers are individual consumers; there is no enterprise customer base. NeuroAge has approximately 10 employees and has raised a disclosed $425K in total funding across three rounds from 2022 to 2024.

Name

NeuroAge Therapeutics

Legal name

NeuroAge Therapeutics, Inc.

Website

https://neuroagetx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroAge Therapeutics sells direct-to-consumer multi-modal brain aging assessments combining cognitive testing, volumetric MRI, proprietary RNA blood biomarkers, and genetic analysis to prevention-minded adults and longevity-focused consumers. Founded in 2022 by MIT/Harvard-trained Dr. Christin Glorioso.

Ownership category

akta.pro rank

Product category

Brain Health Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Services for the Elderly and Persons with Disabilities (624120)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH), Neurology Telemedicine Platforms (HLALAGAC), Cognitive Stimulation & Reminiscence Therapy (Non-Clinical) (HSABAEAH)

Keywords

• Brain health diagnostics
• Cognitive assessment
• Biological age testing
• Longevity biomarkers
• Alzheimer's risk screening

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Direct-to-Consumer Product Sales: NeuroAge sells its assessment products directly to individual consumers through its website and app storefront. Products range from a $9.99/month NeuroGames subscription to comprehensive bundles at $1,398-$3,895. Revenue is primarily one-time purchase for individual components or annual subscription for bundles, with add-on upsells (genome sequencing, additional blood tests, full-body MRI).
2. Clinical Consultation (Coaching): One-on-one virtual coaching sessions with Dr. Christin Glorioso at $280 per 50-minute session. Offered as single sessions or multi-session packages (4 or 12 sessions). Provides personalized recommendations across the 9 Pillars of Healthy Brain Aging based on multi-modal assessment results.
3. ADDF-Funded Clinical Trial: An IRB-approved pilot clinical study funded by the Alzheimer's Drug Discovery Foundation (ADDF), enrolling 75 participants to validate the multi-modal assessment. While not revenue-generating, this funding subsidizes data collection and model validation, indirectly supporting product development and credibility.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

Core offering

NeuroAge Therapeutics operates a multi-modal brain aging assessment platform that combines AI-powered cognitive testing (NeuroGames), volumetric brain MRI analysis, a proprietary 52-transcript RNA blood biomarker panel, and genetic resilience analysis to generate a composite biological brain age score. Products are sold direct-to-consumer via the company's website with optional one-on-one coaching from the founder-physician, supported by a network of 72+ MRI partner centers and Quest Diagnostics for blood draws.

Product overview

NeuroAge Therapeutics offers a multi-modal brain health assessment platform combining seven distinct products/modules: NeuroGames (cognitive assessment and training), Brain MRI (volumetric imaging with AI analysis via BrainKey), Genetic Resilience Analysis (whole-genome sequencing and polygenic risk scoring), AD-Detect Blood Test (Alzheimer's pathology biomarkers via Quest Diagnostics), NeuroAge Blood Test (proprietary 52-RNA brain aging biomarkers), Coaching Program (1:1 sessions with Dr. Glorioso), and the Essential Bundle (discounted combination of MRI, genetics, NeuroGames, and consultation). The products are designed to work independently or as an integrated platform, with results unified into a single NeuroAge score tracked over time. Individual components range from $9.99/month (NeuroGames) to $3,895 (Ultra bundle), with the Essential Bundle ($1,398/year) serving as the flagship bundled offering.

Differentiator

Problem solved

Functional benefit

Brands

• NeuroGames: At-home cognitive assessment and training program for tracking memory, attention, visuospatial performance, executive function, and processing speed over time with personalized recommendations.
• Essential Bundle
• Brain MRI
• Genetic Resilience Analysis
• AD-Detect
• NeuroAge Blood Test
• Coaching Program

Products and services

• NeuroGames At-home cognitive assessment and training program measuring memory, attention, visuospatial performance, executive function, and processing speed. Includes a speed-of-processing training game based on the ACTIVE trial evidence and personalized recommendations. Priced at $9.99/month.
• Essential Bundle Annual multi-modal brain health assessment bundle priced at $1,398/year (saving 20% vs. $1,746). Includes Brain MRI with 3D dashboard, Genetic Resilience analysis, NeuroGames, full score interpretation, personalized recommendations, and a 30-minute virtual consultation.
• Brain MRI Non-contrast, no-radiation volumetric brain MRI analyzed by BrainKey AI across 25+ brain regions with a 3D dashboard and radiologist review for incidental findings (tumors, strokes, aneurysms). $1,398 for a new scan via NeuroAge's partner network, or $399 when uploading an existing compatible MRI.
• Genetic Resilience Analysis Genetic analysis covering APOE genotype, a 41-variant Alzheimer's polygenic risk score, longevity genes (Klotho, FOXO3, CETP, IGF1R, IL-6, mTOR, PCSK9), pharmacogenomic markers (MTHFR, CYP2C19, CYP2C9, SLCO1B1, VKORC1, HLA-B*15:02), and broader disease risks. $249 with existing sequencing data, $799 with 30x whole-genome sequencing add-on.
• AD-Detect Blood Test Alzheimer's-specific blood test measuring plasma amyloid ratios (Aβ42/40) and phosphorylated tau (p-tau181 and p-tau217) via the Quest Diagnostics phlebotomy workflow. Achieves 91% sensitivity and 91% specificity for amyloid PET positivity. Priced at $799.
• NeuroAge Blood Test Proprietary blood test measuring 52 RNA biomarkers tracking brain aging hallmarks (synaptic decline, DNA damage, mitochondrial dysfunction, neuroinflammation, cellular senescence, stress response). Developed from brain-blood paired cohorts and unique to NeuroAge. Priced at $899.
• Coaching Program One-on-one virtual coaching with Dr. Christin Glorioso at $280 per 50-minute session, available in 1, 4, or 12 session tiers. Provides personalized recommendations across the 9 Pillars of Healthy Brain Aging based on multi-modal assessment results.
• NeuroAge Test Ultra Comprehensive one-time multi-modal brain health workup at $3,895, combining Brain MRI, Genetic Resilience Analysis, NeuroAge Blood Test, AD-Detect, NeuroGames, and integrated interpretation in a single purchase.

Quantifiable outcome

• Being 5+ years younger biologically than chronological brain age is associated with approximately 6-fold lower risk of Alzheimer's disease, Parkinson's disease, and age-related cognitive decline, even in APOE ε4 carriers (Glorioso et al., 2019, Life Science Alliance).
• +7 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability8 records

Feature5 records

Partnerships

27 partnerships are on record, tiered core and minor.

• BrainKeycoreTechnology or IntegrationNeuroAge uses BrainKey's AI-powered platform for MRI volumetric analysis across 25+ brain regions, 3D visualization, and brain age estimation. BrainKey was founded by Dr. Owen Phillips (Stanford-trained neuroscientist) and backed by Y Combinator. Every MRI through NeuroAge's partner network includes BrainKey analysis and radiologist screening for incidental findings.
• Quest DiagnosticscoreTechnology or IntegrationNeuroAge's AD-Detect blood test uses the Quest Diagnostics workflow for standard blood draws to measure Aβ42/40 and p-tau217 biomarkers. Quest's clinical laboratory infrastructure enables accessible phlebotomy across the US for NeuroAge's Alzheimer's-specific blood test.
• River Oaks MRI & DiagnosticsminorChannel Partner/ Reseller/ DistributorOne of 72+ MRI imaging partner centers in NeuroAge's network. River Oaks MRI provides brain MRI scanning services for NeuroAge customers in its geographic area.
• Dr. Joseph Debe's CenterminorChannel Partner/ Reseller/ DistributorClinical partner that integrates NeuroAge's multi-modal brain health assessment into its practice. Referenced as a partner clinic on NeuroAge's website.
• PhysioAgeminorChannel Partner/ Reseller/ DistributorLongevity clinic partner integrating NeuroAge's brain health testing into its multi-modal longevity assessment programs.
• Carnegie Mellon University (Pfenning Lab)minorStrategic or Co-development PartnerResearch partnership with CMU's Pfenning Lab for computational biology and genomics analysis. The lab is listed as a partner on NeuroAge's website.
• Prime Health AssociatesminorChannel Partner/ Reseller/ DistributorClinical partner integrating NeuroAge brain health testing into its functional medicine and longevity practice.
• HealthspanSFminorChannel Partner/ Reseller/ DistributorSan Francisco-based longevity clinic partner offering NeuroAge's multi-modal brain health assessment to its clients.
• Cure MAPT FTDminorStrategic or Co-development PartnerNonprofit research partner focused on MAPT and frontotemporal dementia. Listed as a partner on NeuroAge's website, indicating alignment on dementia research and patient referrals.
• R42 AI & Longevity ClubminorStrategic or Co-development PartnerCo-founded by Dr. Ronjon Nag (NeuroAge advisor), R42 is a longevity-focused investment and community platform. NeuroAge participated in the R42 Healthcare Retreat at Half Moon Bay, where Dr. Glorioso coordinated brain MRI and cognitive testing for attendees.
• HumanautminorChannel Partner/ Reseller/ DistributorLongevity health company partnered with NeuroAge. Dr. Amy Killen (CMO of Humanaut) is a featured speaker at the Younger 2027 contest kickoff.
• Raffaele MedicalminorChannel Partner/ Reseller/ DistributorMedical clinic partner integrating NeuroAge's brain health assessments into its clinical offerings.
• LabXMDminorChannel Partner/ Reseller/ DistributorMedical laboratory partner referenced in NeuroAge's partner network.
• The Phoenix CommunityminorChannel Partner/ Reseller/ DistributorCommunity wellness organization partner with affiliate arrangement (aff=NEUROAGE2025).
• Lutanen HealthminorChannel Partner/ Reseller/ DistributorLongevity and health clinic partner. Listed as a sponsor and partner of the Younger 2027 contest, offering a 1-year membership as a prize.
• Precision Medical CareminorChannel Partner/ Reseller/ DistributorPrecision medicine clinic partner integrating NeuroAge brain health testing.
• Central Park Advanced ImagingminorChannel Partner/ Reseller/ DistributorMRI imaging center partner in NeuroAge's partner network.
• Jona (Human Longevity, Inc.)minorChannel Partner/ Reseller/ DistributorMicrobiome testing partner offering joint promotions with NeuroAge (discount/NeuroAgeTx50).
• TruDiagnosticcoreStrategic or Co-development PartnerTesting partner for the Younger 2027 contest, providing the TruAge platform (epigenetic clocks, SymphonyAge, TruHealth clinical biomarkers) for measuring participants' biological age. TruDiagnostic's platform was developed with academic collaborators including Harvard T.H. Chan School of Public Health and Yale School of Medicine.
• FaceAge (Harvard/Mass General Brigham)coreStrategic or Co-development PartnerFaceAge is a deep-learning face-age estimation model developed by Dr. Ray Mak (Harvard/Mass General Brigham) for the Younger 2027 contest. FaceAge translates standardized face photos into a biological age estimate, validated in cancer patient cohorts and published in The Lancet Digital Health (2025) and JAMA Network Open (2026).
• Vero BiosciencecoreStrategic or Co-development PartnerTesting partner for the Younger 2027 contest's Ultra panel, providing proteomic organ age clocks developed in the Wyss-Coray lab at Stanford. Vero's clocks are not yet commercially available; Ultra Competitors get world-first access.
• Yale (Sehgal Lab)coreStrategic or Co-development PartnerDr. Raghav Sehgal's lab at Yale is providing next-generation methylation-based aging clocks for the Younger 2027 Ultra panel. These clocks are not yet commercially available.
• CoreVivaminorChannel Partner/ Reseller/ DistributorWhole-body MRI partner for the Younger 2027 contest. CoreViva is providing a whole-body MRI scan as a prize for contest winners.
• Viome Life SciencesminorChannel Partner/ Reseller/ DistributorLongevity technology partner and sponsor of the Younger 2027 contest. Viome is providing a gut and cellular health kit as a prize.
• Longevity.GlobalminorGTM or Marketing PartnerMedia partner for the Younger 2027 contest, founded by Dr. Christin Glorioso. Provides media coverage and audience reach for the longevity-focused event.
• Lifespan.iominorGTM or Marketing PartnerMedia partner for the Younger 2027 contest. Lifespan.io covers longevity science and provides editorial coverage and audience reach for the event.
• Monarch Athletic ClubminorChannel Partner/ Reseller/ DistributorAthletic club partner referenced in NeuroAge's partner network.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Prenuvo: Prenuvo offers full-body MRI screening including brain MRI as a direct-to-consumer longevity assessment, with similar premium pricing and HSA/FSA eligibility. NeuroAge explicitly references Prenuvo in its MRI upload credit integration, indicating direct competition in the brain-MRI consumer space.
• Ezra: Ezra provides AI-enhanced full-body MRI screening as a direct-to-consumer service, including brain scans, at premium subscription pricing. NeuroAge's MRI product integrates Ezra uploads, confirming both compete in the same brain-MRI consumer category.
• Function Health: Function Health sells comprehensive lab-based preventive health panels to consumers with a similar longevity-focused value proposition, recurring testing model, and premium pricing. Both companies target prevention-minded adults seeking longitudinal biological insight.
• TruDiagnostic: TruDiagnostic is a direct competitor in biological age testing, offering epigenetic clocks (TruAge) and clinical biomarkers for consumers and researchers. TruDiagnostic is also NeuroAge's testing partner for the Younger 2027 contest, reflecting overlapping positioning.
• Elysium Index: Elysium Index is a biological age testing service combining multiple biomarkers, including epigenetic and blood-based measures, targeting the same longevity-optimization consumer segment as NeuroAge's multi-modal platform.
• Human Longevity Inc. (Jona): HLI / Jona offers comprehensive whole-body and brain assessments combining imaging, genomics, and blood biomarkers for premium longevity-focused consumers. NeuroAge lists Jona as a co-marketing partner, confirming they compete and collaborate in the same space.
• InsideTracker: InsideTracker delivers blood biomarker analysis with personalized longevity and performance recommendations through a direct-to-consumer subscription model. It competes with NeuroAge's blood-based RNA panel and coaching layer for the same health-optimization persona.
• Fountain Life: Fountain Life operates premium preventive longevity centers offering whole-body MRI, advanced blood diagnostics, and AI-driven health insights — overlapping heavily with NeuroAge's multi-modal assessment offering at higher price points and broader physical footprint.

Emerging players

• Viome Life Sciences: Viome sells gut microbiome and cellular health testing direct-to-consumer with personalized recommendations — an adjacent category in the longevity D2C testing market. Viome is also a Younger 2027 contest partner, indicating collaboration alongside partial overlap.

Others

• BrainKey: BrainKey provides AI-powered volumetric MRI analysis across 25+ brain regions and is NeuroAge's core technology integration for brain-age estimation. Rather than a competitor, BrainKey is an enabling supplier — included here because it sits in the same brain-volumetrics category and could evolve into a competing product.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/NeuroAgeTX
• YouTubeyoutube.com/@NeuroAgeTherapeutics-gp3ug
• Facebookfacebook.com/share/18kkp49YoA
• LinkedInlinkedin.com/company/neuroage-therapeutics
• Instagraminstagram.com/neuroage_therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroAge Therapeutics